Abstract
eIF4E is essential for translation initiation, but its overexpression causes malignant transformation. Recent work demonstrated that eIF4E/F participates in exposing and locating alternate translation start codons during scanning. Translation initiation of several important protooncogenes and growth-regulators, such as Myc and FGF-2, can start at CUG start codon(s) upstream of the normal open reading frame (ORF). The resulting amino-terminal extension alters the properties of these proteins and their intracellular distribution. In cells overexpressing eIF4E, c-myc is overexpressed and particularly the larger, CUG-initiated form (Myc1). Recent reports suggest that synthesis of Myc2, the normally expressed AUG-initiated form, is mediated by an IRES. To determine what role eIF4E might play in c-myc expression, the c-myc 5′ untranslated region (UTR) was fused in-frame to CAT reporters, and several more derivative constructs were made. In vitro translation experiments (with and without eIF4E/F); expression in CHO cells transformed with eIF4E; and deletion/mutation analysis demonstrated that Myc1 is translated by a scanning mechanism, while Myc2 is translated by Internal Ribosome Repositioning. Moreover, the existence of a true IRES in the 5′UTR was contradicted by its failure to direct translation of a circular transcript, in contrast to hsp70. The c-myc 5′UTR also failed to engage in translation in the absence of functional eIF4F, after cleavage of the eIF4G component with CVB4 protease-2A. The Internal Repositioning Element (IRPE) in c-myc 5′UTR was delimited to nucleotides (nt) 394 – 440 from the P1 transcription start site.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout




Similar content being viewed by others
References
Acland P, Dixon M, Peters G and Dickson C. . 1990 Nature 343: 662–665.
Ar-Rushdi A, Nishakura K, Erickson J, Watt R, Rovera G and Croce C. . 1983 Science 222: 390–393.
Bentley DL and Groudine M. . 1986 Nature 321: 702–706.
Borman AW and Kean KM. . 1997 Virology 237: 129–136.
Chen CY and Sarnow P. . 1995 Science 268: 415–417.
Clemens MJ. . 1987 In: Transcription and Translation: A practical approach, Rickwood D and Hanes BD (eds).. IRL Press Ltd. Oxford pp. 263–276.
Dalla-Favera R, Baregni M, Erikson J, Patterson D, Gallo RC and Croce C. . 1982 Proc. Natl. Acad. Sci. USA 79: 7824–7827.
De Benedetti A, Joshi-Barve S, Rinker-Schaeffer CW and Rhoads RE. . 1991 Mol. Cell. Biol. 11: 5435–5445.
De Benedetti A, Joshi-Barve S, Graff JR and Zimmer SG. . 1994 Mol. Cell. Diff. 2: 347–371.
Dosaka-Akita H, Rosenberg RK, Minna JD and Birrer MJ. . 1991 Oncogene 6: 371–378.
Florkiewicz RZ and Sommer A. . 1989 Proc. Natl. Acad. Sci. USA 86: 3978–3981.
Fraser SD, Wilkes-Johnston J and Browder LW. . 1996 Oncogene 12: 1223–1230.
Fütterer J, Kiss-László Z and Hohn T. . 1993 TIBS 22: 177–181.
Gandori C and Eisenman RN. . 1997 TIBS 22: 177–181.
Hann SR, Dixit M, Sears RC and Sealy L. . 1994 Gene Dev. 8: 2441–2452.
Hann SR, King MW, Betley DL, Anderson CW and Eisenman RN. . 1988 Cell 52: 185–195.
Jackson RJ. . 1996 In: Translational Control, Hershey JWB, Mathews MB and Sonenberg N, Rickwood D and Hanes BD (eds).. Cold Spring Harbor: Cold Spring Harbor Laboratory Press pp. 71–112.
Joshi-Barve S, De Benedetti A and Rhoads RE. . 1992 J. Biol. Chem. 267: 21038–21043.
Kevil C, Carter P Hu B and De Benedetti A. . 1995 Oncogene 11: 2339–2348.
Koromilas AE, Lazaris-Karatzas A and Sonenberg N. . 1992 EMBO J. 11: 4153–4158.
Kozak M. . 1978 Cell 15: 1109–1123.
Kozak M. . 1990 Proc. Natl. Acad. Sci. USA 87: 8301–8305.
Lamphear BJ and Rhoads RE. . 1996 Biochemistry 35: 15726–15733.
Latorre P, Kolakofsky D and Curran J. . 1998 Mol. Cell. Biol. 18: 5021–5031.
Lazarus P. . 1992 Oncogene 7: 1037–1041.
Mellentin JD, Smith SD and Cleary ML. . 1989 Cell 58: 77–83.
Mendez R, Kollmorgen G, White MF and Rhoads RE. . 1997 Mol. Cell. Biol. 17: 5184–5192.
Nanbru C, Lafon I, Audiger S, Gensac M-C, Vagner S, Huez G and Prats A-C. . 1997 J. Biol. Chem. 272: 32061–32066.
Nathan C-A, Carter P, Liu L, Li BD, Abreo F, Tudor A, Zimmer SG and De Benedetti A. . 1997 Oncogene 15: 1087–1094.
Parkin N, Darveau A, Nicoloson R and Sonnenberg N. . 1988 Mol. Cell Biol. 8: 2875–2883.
Paulin FEM, West MJ, Sullivan NF and Willis AE. . 1996 Oncogene 13: 505–513.
Pause A and Sonnenberg N. . 1993 Curr. Opin. Structural Biol. 3: 953–959.
Penn LJZ, Brooks, MW, Laufer, EM and Land H. . 1990 EMBO. J. 9: 1113–1121.
Reddy, KS and Sulcova V. . 1997 Cancer Genet. Cytogenet. 95: 206–209.
Rhoads, RE. . 1993 J. Biol. Chem. 266: 3017–3020.
Saris CM, Domen J and Berns A. . 1991 EMBO J. 10: 655–664.
Stonely M, Paulin FEM, Le Quesne JPC, Chappell SA and Willis AE. . 1998 Oncogene 16: 423–428.
Taub R, Kirsh I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S and Leder P. . 1982 Proc. Natl. Acad. Sci. USA 79: 7837–7841.
West M, Sullivan NF and Willis AE. . 1995 Oncogene 11: 2515–2524.
West MJ, Stoneley M and Willis AE. . 1998 Oncogene 17: 769–780.
Yueh A and Schneider RJ. . 1996 Gen. Dev. 10: 1557–1567.
Zuker M. . 1989 In: Methods in Enzymology, Dahlberg and Abelson (eds). Academic Press, New York. pp. 262–288.
Acknowledgements
We are indebted to Nissim Hay (University of Chicago) for the human c-myc cDNA; Richard Jackson (University of Cambridge) for the pXLJ – EMC bicistronic construct; Rick Morimoto (Northwestern University) for the human hsp70 cDNA; Bhavesh Joshi (Marine Biotechnology Institute, Baltimore) for the pREP11 construct; Warren Bryce (Abbot Laboratories, North Chicago) for the rabbit c-Myc antiserum; Barry Lamphear (LSUMC) for the CVB4 protease 2A. This work was supported by NSF grant MCB9513756 and NIH grant CA69148-01A1.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carter, P., Jarquin-Pardo, M. & De Benedetti, A. Differential expression of Myc1 and Myc2 isoforms in cells transformed by eIF4E: evidence for internal ribosome repositioning in the human c-myc 5′UTR. Oncogene 18, 4326–4335 (1999). https://doi.org/10.1038/sj.onc.1202890
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1202890
Keywords
This article is cited by
-
Effects of protein phosphorylation on ubiquitination and stability of the translational inhibitor protein 4E-BP1
Oncogene (2008)
-
Initiation factor modifications in the preapoptotic phase
Cell Death & Differentiation (2005)
-
Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death
Molecular and Cellular Biochemistry (2005)
-
Targets and mechanisms for the regulation of translation in malignant transformation
Oncogene (2004)
-
eIF-4E expression and its role in malignancies and metastases
Oncogene (2004)


